for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Almirall SA

ALM.MC

Latest Trade

12.73EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

8.84

 - 

15.35

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Latest Developments

Almirall's 2.1% Senior Notes Issue Due 2026 Has Been Closed And Paid At 300 Mln Euros

Sept 22 (Reuters) - Almirall SA <ALM.MC>::ISSUANCE OF ITS 2.125% SENIOR NOTES IN AGGREGATE PRINCIPAL AMOUNT OF 300 MILLION EUROS DUE 2026 HAS BEEN CLOSED AND PAID.

Almirall Announces Issuance Of 250 Mln Euros Senior Notes Due 2026

Sept 13 (Reuters) - Almirall SA <ALM.MC>::CARRIES OUT AN ISSUANCE OF SENIOR NOTES IN AN AGGREGATE MAXIMUM PRINCIPAL AMOUNT OF 250 MILLION EUROS DUE 2026.PROCEEDS FROM OFFERING WOULD BE USED TO REPAY IN FULL AND CANCEL 250 MILLION EUROS BONDS DUE DEC 2021 AND PAY TRANSACTION FEES AND EXPENSES.NOTES WILL BE OFFERED ONLY TO QUALIFIED INSTITUTIONAL BUYERS.

Almirall Says Primary And All Key Secondary Endpoints Met In Phase 3 Trials Of Lebrikizumab To Treat Atopic Dermatitis

Aug 16 (Reuters) - Almirall SA <ALM.MC>::LEBRIKIZUMAB SIGNIFICANTLY IMPROVED SKIN CLEARANCE AND ITCH IN PEOPLE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS IN TWO PHASE 3 TRIALS.PRIMARY AND ALL KEY SECONDARY ENDPOINTS INCLUDING ITCH, INTERFERENCE OF ITCH ON SLEEP AND QUALITY OF LIFE WERE MET AT WEEK 16 IN TWO PIVOTAL PHASE 3 TRIALS.SAFETY PROFILE CONSISTENT WITH PRIOR LEBRIKIZUMAB STUDIES IN ATOPIC DERMATITIS.THE U.S. FDA HAS GRANTED FAST TRACK DESIGNATION TO LEBRIKIZUMAB FOR MODERATE-TO-SEVERE AD IN ADULT AND ADOLESCENT PATIENTS.IT HAS LICENSED RIGHTS TO DEVELOP AND COMMERCIALIZE LEBRIKIZUMAB FOR TREATMENT OF DERMATOLOGY INDICATIONS, INCLUDING AD, IN EUROPE.LILLY HAS EXCLUSIVE RIGHTS FOR DEVELOPMENT AND COMMERCIALIZATION OF LEBRIKIZUMAB IN THE UNITED STATES AND REST OF WORLD OUTSIDE EUROPE.DATA FROM PHASE 3 COMBINATION STUDY (ADHERE) OF LEBRIKIZUMAB WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH AD WILL BE AVAILABLE LATER THIS YEAR.

Almirall H1 Net Result Turns To Loss Of 42.8 Mln Euros YoY

July 26 (Reuters) - ALMIRALL <ALM.MC>: :H1 REVENUE 427.8 MILLION EUROS VERSUS 433.0 MILLION EUROS YEAR AGO.H1 NET LOSS 42.8 MILLION EUROS VERSUS PROFIT 42.4 MILLION EUROS YEAR AGO.H1 EBITDA 136.6 MILLION EUROS VERSUS 137.2 MILLION EUROS YEAR AGO.

Almirall Upgrades 2021 Full Year Core Guidance

July 26 (Reuters) - Almirall SA <ALM.MC>::SEES 2021 FULL YEAR CORE GUIDANCE UPGRADED.SEES 2021 CORE NET SALES MID SINGLE-DIGIT GROWTH VERSUS PREVIOUS YEAR (€755 MILLION).SEES 2021 CORE EBITDA BETWEEN €195 MILLION - €215 MILLION (PREVIOUSLY BETWEEN €190 MILLION - €210 MILLION).EXPECTS COVID-19 TO CONTINUE TO HAVE AN IMPACT, WITH PROGRESSIVE NORMALIZATION IN H2 2021.H1 NORMALIZED NET PROFIT 57.8 MILLION EUROS VERSUS 59.5 MILLION EUROS YEAR AGO.

Almirall Gets EU Commission Approval For Actinic Keratosis Topical Treatment Klisyri

July 19 (Reuters) - Almirall SA <ALM.MC>::RECEIVES EUROPEAN COMMISSION APPROVAL FOR KLISYRI (TIRBANIBULIN), AN INNOVATIVE TOPICAL TREATMENT FOR ACTINIC KERATOSIS.IN ADDITION, CO HAS SUBMITTED KLISYRI FOR A MARKETING AUTHORISATION IN SWITZERLAND IN Q4 2020 AND DOSSIER IS CURRENTLY UNDER REVIEW BY SWISSMEDIC.COMPANY HAS ALREADY SUBMITTED IN GREAT BRITAIN VIA THE EUROPEAN COMMISSION DECISION RELIANCE PROCEDURE.

Almirall And MC2 Therapeutics Announce Completion Of Decentralized Procedure In Europe For Treatment Of Psoriasis Vulgaris In Adults

July 6 (Reuters) - Almirall SA <ALM.MC>::ALMIRALL AND MC2 THERAPEUTICS ANNOUNCE COMPLETION OF DECENTRALIZED PROCEDURE IN EUROPE FOR TOPICAL TREATMENT OF MILD TO MODERATE PSORIASIS VULGARIS IN ADULTS.SUCCESSFUL COMPLETION OF A DECENTRALIZED PROCEDURE IS FINAL STEP BEFORE NATIONAL MARKETING AUTHORIZATIONS CAN BE GRANTED BY EUROPEAN COUNTRIES.

Almirall And Kaken Pharmaceutical Enter Into Agreement For European Rights To Topical Formulation Of Efinaconazole

July 1 (Reuters) - Almirall SA <ALM.MC>::ALMIRALL AND KAKEN PHARMACEUTICAL ENTER INTO A LICENSE AND DISTRIBUTION AGREEMENT FOR EUROPEAN RIGHTS TO THE TOPICAL FORMULATION OF EFINACONAZOLE.KAKEN PHARMACEUTICAL GRANTS CO THE EXCLUSIVE RIGHT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF THE TOPICAL FORMULATION EFINACONAZOLE IN EUROPE.UNDER AGREEMENT, KAKEN PHARMACEUTICAL RECEIVES UPFRONT CASH PAYMENT AND HAS POTENTIAL TO RECEIVE MILESTONE PAYMENTS AND ROYALTIES ON NET SALES OF PRODUCT.PLANS TO HAVE A PRE-SUBMISSION MEETING WITH REGULATORY AUTHORITIES TO PREPARE APPROVAL OF PRODUCT IN EUROPE WITHIN NEXT 12 MONTHS.TRIAZOLE ANTIFUNGAL COMPOUND DISCOVERED BY KAKEN PHARMACEUTICAL IS INDICATED FOR TREATMENT OF ONYCHOMYCOSIS, FUNGAL INFECTION OF NAIL.

Almirall Says Holders Of 64.35% Of Free Allotment Rights Opt To Receive New Shares

June 3 (Reuters) - Almirall SA <ALM.MC>::SAYS HOLDERS OF 64.35% OF FREE ALLOTMENT RIGHTS HAVE OPTED TO RECEIVE NEW SHARES.DEFINITIVE NUMBER OF ORDINARY SHARES WITH PAR VALUE OF 0.12 EUROS PER ISSUED UNIT IN BONUS ISSUE IS 1.7 MILLION, CORRESPONDING TO 0.93% OF SHARE CAPITAL PRIOR TO CAPITAL INCREASE.SAYS CAPITAL INCREASE AMOUNTS TO 0.2 MILLION EUROS.SHAREHOLDERS OWNING REMAINING 35.65% OF FREE-OF-CHARGE ALLOCATION RIGHTS HAVE ACCEPTED IRREVOCABLE COMMITMENT TO BUY RIGHTS ASSUMED BY ALMIRALL.

Almirall Receives Positive CHMP Opinion For Klisyri, A Topical Treatment For Actinic Keratosis

May 21 (Reuters) - Almirall SA <ALM.MC>::RECEIVES POSITIVE OPINION FROM COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF EUROPEAN MEDICINES AGENCY FOR KLISYRI, A TOPICAL TREATMENT FOR ACTINIC KERATOSIS.THE CHMP OPINION IS BASED ON TWO PHASE III STUDIES POSITIVE RESULTS.APPROVAL OF KLISYRI (TIRBANIBULIN) IS EXPECTED IN ABOUT 60 DAYS AND ITS LAUNCH IN EUROPE COULD TAKE PLACE IN LATE 2021.SUBMITTED IT FOR A MARKETING AUTHORIZATION IN SWITZERLAND IN Q4 2020 AND THE DOSSIER IS CURRENTLY UNDER REVIEW BY SWISSMEDIC.WILL ALSO SUBMIT IT IN GREAT BRITAIN VIA EUROPEAN COMMISSION DECISION RELIANCE PROCEDURE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up